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Angiogenesis, new blood vessel formation from preexisting vessels, is critical for solid
tumor growth. As such, there have been efforts to inhibit angiogenesis as a means to
obstruct tumor growth. However, antiangiogenic therapy faces major challenges to the
selective targeting of tumor-associated-vessels, as current antiangiogenic targets also
disrupt steady-state vessels. Here, we demonstrate that the developmentally critical
transcription factor Etv2 is selectively upregulated in both human and mouse tumor-
associated endothelial cells (TAECs) and is required for tumor angiogenesis. Two-photon
imaging revealed that Etv2-deficient tumor-associated vasculature remained similar to that
of steady-state vessels. Etv2-deficient TAECs displayed decreased Flk1 (also known as
Vegfr2) expression, FLK1 activation, and proliferation. Endothelial tube formation,
proliferation, and sprouting response to VEGF, but not to FGF2, was reduced in Etv2-
deficient ECs. ROS activated Etv2 expression in ECs, and ROS blockade inhibited Etv2
expression in TAECs in vivo. Systemic administration of Etv2 siRNA nanoparticles potently
inhibited tumor growth and angiogenesis without cardiovascular side effects. These studies
highlight a link among vascular oxidative stress, Etv2 expression, and VEGF response that
is critical for tumor angiogenesis. Targeting the ETV2 pathway might offer a unique
opportunity for more selective antiangiogenic therapies.
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Introduction
Angiogenesis is an important process for successful embryogenesis, postinjury tissue repair and regen-
eration, and progression of  many pathologic conditions, including cancer. Thus, while promotion of  
angiogenesis is critical to tissue repair and regeneration, inhibition of  angiogenesis is important to 
obstruct pathologic conditions, such as for tumor growth. Currently, it remains a challenge to selec-
tively target tumor angiogenesis, as many of  the factors and pathways presently targeted in therapies 
are shared between normal and tumor vessels (1–3). For example, anti-VEGF therapies, although con-
sidered to be most prevalent in inhibiting tumor angiogenesis, have severe shortcomings in specifically 
targeting tumor-associated vessels undergoing neoangiogenesis (4, 5), as VEGF is also required for 
physiological steady-state vessels (6, 7). Considering these limitations, it would be crucial to identify 
molecular marker(s) and signaling pathways uniquely functioning in tumor-associated vessels that can 
be exclusively targeted.
ETS transcription factors have emerged as critical regulators of  angiogenesis (8–10). A winged helix-turn-
helix motif  formed by the ETS domain can bind a consensus sequence (GGAA/T) to regulate target gene 
expression (11). Many ETS factors are redundantly expressed in hematopoietic and endothelial cells (ECs) 
in the developing embryo (12, 13). Consistently, mice or zebrafish deficient in any of  these Ets factors display 
Angiogenesis, new blood vessel formation from preexisting vessels, is critical for solid tumor 
growth. As such, there have been efforts to inhibit angiogenesis as a means to obstruct tumor 
growth. However, antiangiogenic therapy faces major challenges to the selective targeting of tumor-
associated-vessels, as current antiangiogenic targets also disrupt steady-state vessels. Here, we 
demonstrate that the developmentally critical transcription factor Etv2 is selectively upregulated 
in both human and mouse tumor-associated endothelial cells (TAECs) and is required for tumor 
angiogenesis. Two-photon imaging revealed that Etv2-deficient tumor-associated vasculature 
remained similar to that of steady-state vessels. Etv2-deficient TAECs displayed decreased Flk1 
(also known as Vegfr2) expression, FLK1 activation, and proliferation. Endothelial tube formation, 
proliferation, and sprouting response to VEGF, but not to FGF2, was reduced in Etv2-deficient ECs. 
ROS activated Etv2 expression in ECs, and ROS blockade inhibited Etv2 expression in TAECs in 
vivo. Systemic administration of Etv2 siRNA nanoparticles potently inhibited tumor growth and 
angiogenesis without cardiovascular side effects. These studies highlight a link among vascular 
oxidative stress, Etv2 expression, and VEGF response that is critical for tumor angiogenesis. 
Targeting the ETV2 pathway might offer a unique opportunity for more selective antiangiogenic 
therapies.
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varying degrees of  hematopoietic and vascular defects (14), probably reflecting the redundant expression pat-
tern of  these Ets factors in hematopoietic cells and ECs. Distinct from these ETS factors, Etv2 (also known as 
Er71 and Etsrp) is transiently expressed in the primitive streak, yolk sac blood islands, and large vessels of  the 
dorsal aorta during embryogenesis (15–18). Etv2-deficient mice display a complete block in blood and blood 
vessel formation, demonstrating that ETV2 performs a nonredundant and indispensable function in hema-
topoietic and vessel development. We recently established that ETV2 activates other Ets transcription factors 
in hematopoietic cell and EC lineage development. Moreover, the hematopoietic and EC program induced 
by ETV2 is maintained by other ETS factors through an ETS switching mechanism in the face of  transient 
Etv2 expression (19). Importantly, ETV2 function is evolutionary conserved, as mouse or human Etv2 can 
induce hematopoietic and vascular development in zebrafish (20). Notably, ECs can be efficiently generated 
from mouse and human pluripotent stem cells by enforced Etv2 expression (17, 21, 22). Moreover, Etv2 can 
efficiently reprogram somatic cells to ECs (23–26). These studies have established that Etv2 is necessary and 
sufficient for EC generation and function.
While Etv2 function in the developmental context has been extensively investigated (27, 28), studies 
on this gene in adults are greatly lacking. Previous studies have established that Etv2 expression becomes 
silent once hematopoietic cells and ECs have been generated (17, 29–31). However, it becomes reactivated 
upon injury and is required for hematopoietic and EC regeneration (32, 33). Since developmental programs 
are often reactivated in pathological conditions and regulate disease progression, we investigated whether 
the developmentally critical factor Etv2 is also reactivated in tumor endothelium and is required for tumor 
angiogenesis. Our data demonstrated that ETV2 is expressed in human and mouse tumor-associated ECs 
(TAECs). Endothelial Etv2 is required for tumor angiogenesis. While Etv2-deficient TAECs failed to elevate 
Flk1 expression and had a defective response to VEGF, they displayed a normal response to FGF. We iden-
tified ROS, which were readily elevated in TAECs, as upstream activators of  Etv2 expression. Systemic Etv2 
siRNA nanoparticle delivery effectively inhibited tumor growth and angiogenesis without cardiovascular 
side effects. Our results indicate that Etv2 is a marker for TAECs and that targeting Etv2 maybe a valid 
choice for blocking tumor angiogenesis.
Results
Etv2 is upregulated in both human and mouse TAECs. As Etv2 was required for ECs undergoing active angio-
genesis (32), we assessed whether Etv2 also plays a role in tumor angiogenesis. We first examined human 
malignant and matched nonmalignant specimens from lung, breast, prostate, and colon cancer patients 
and found that ETV2 was expressed in the tumor vessels but not in the nonmalignant tissues (Figure 1, 
A–D). We next determined the kinetics of  Etv2 expression in a mouse tumor transplantation model using 
Lewis lung carcinoma–GFP (LLC-GFP) tumor cells. In this tumor transplantation model, palpable tumor 
mass is detected by days 4–5 after tumor cell transplantation (ptt), followed by robust tumor growth. Etv2 
expression was detected in the tumor mass from day 4 ptt, with its expression highly upregulated from 
day 10 ptt (Supplemental Figure 1A; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.97349DS1). We analyzed the FACS-sorted ECs from the tumor by quantitative 
real-time reverse-transcription PCR (qRT-PCR) and found that TAECs expressed high levels of  Etv2 (Fig-
ure 1E). Immunofluorescence of  the mouse tumor sections also revealed that ETV2 was present primarily 
in TAECs (Figure 1F). Intriguingly, ETV2 was also detected in some, not all, hematopoietic cells (Supple-
mental Figure 1B). It is notable that ETV2 was present in both nuclei and perinuclear spaces (Supplemental 
Figure 1, C and D). Since tumor cells and ECs in nonmalignant vessels do not express Etv2 (Figure 1, A–D, 
and Supplemental Figure 1A), we conclude that Etv2 expression is induced in TAECs.
Endothelial Etv2 is required for optimal tumor growth. To determine whether the reactivation of  Etv2 
expression in TAECs reflected its functional requirement in tumor angiogenesis, we transplanted LLC-
GFP cells into Tie2-Cre;Etv2f/f (Tie2-Cre;Etv2 conditional KO [CKO], lacks Etv2 in ECs and hematopoietic 
cells) and VECadherin-Cre;Etv2f/f (VEC-Cre;Etv2 CKO, lacks Etv2 in ECs) mice (32, 33). Efficient deletion 
of  Etv2 was confirmed in ECs of  both models (Supplemental Figure 2A). Etv2 expression in TAECs and 
tumor growth were significantly reduced in the Etv2 CKO mice (Tie2-Cre or VEC-Cre) compared with 
littermate control wild-type mice (Figure 2, A and B, and Supplemental Figure 2B). Similar tumor growth 
defects were observed with another well-studied B16 melanoma tumor model (Supplemental Figure 2C). 
Capillary densities within tumors were also significantly decreased (Figure 2C), suggesting that endothe-
lial Etv2 is required for efficient tumor angiogenesis and growth. Ets transcription factors are redundantly 
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Figure 1. Etv2 is upregulated in tumor endothelial cells. (A–D), Representative images for ETV2 (green) and CD31 (red) immunofluorescence of malignant 
and matched nonmalignant specimens from (A) lung, (B) breast, (C) colon, and (D) prostate cancer patients. DAPI (blue) is used to counterstain nuclei. 
Associated graphs show the quantification of ETV2-expressing CD31+ vessels in malignant versus nonmalignant tissues. Every cancer type had malignant 
and nonmalignant tissue specimen pairs collected from at least 3 patients; at least 3 sections from each patient were subjected to immunofluorescence. 
(E) qRT-PCR analysis of Etv2 expression in CD31+CD45– endothelial cells obtained from lung (LEC) and tumor (TAEC), 10 and 13 days after tumor cell 
transplantation (n = 3 LEC, 7 TAEC day 10, and 6 TAEC day 13). (F) Representative images for ETV2 (green) and CD31 (red) immunofluorescence of mouse 
tumor and lung sections, processed after 20 days of tumor transplantation. LLC-GFP cells (blue) and nuclei counterstained with DAPI (gray) are shown (n = 
15 or more/group). Scale bars: 100 μm; 50 μm (higher-magnification images). Data are presented as mean with standard deviation for all measurements. 
Statistical significance was analyzed by either a 2-tailed Student’s t test (A–D and F) or 1-way ANOVA with Dunnett’s multiple-comparison test (E).
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expressed in ECs (12, 13). Notably, Etv2-deficient TAECs had elevated expression of  Fli1, Erg, and Ets1 
(Figure 2D), suggesting that there might be possible compensatory roles played by the other Ets factors 
in the absence of  the Etv2, which could have contributed to the residual tumor growth in the Etv2-CKO 
mice. Hematopoietic Etv2 also appears to contribute to tumor progression, as Tie2-Cre;Etv2-CKO mice dis-
played more severe reduction in tumor growth than the VEC-Cre;Etv2-CKO mice. Indeed, Vav-Cre;Etv2f/f 
(Vav-Cre;Etv2 CKO, Etv2 deletion in hematopoietic cells) mice showed a mild, but significant, reduction in 
tumor growth and angiogenesis compared with littermate control mice (Supplemental Figure 2, D and E). 
Importantly, tumor-associated hematopoietic cells in the Vav-Cre;Etv2 mice had diminished expressions 
of  angiogenic growth factors Vegf-a, Vegf-b, Fgf-2, Igf-1, and Igf-2 (Supplemental Figure 2F), which could 
explain why mice with deleted hematopoietic Etv2 displayed defective tumor angiogenesis.
Figure 2. Endothelial Etv2 is required for tumor growth and angiogenesis. (A) qRT-PCR analysis of Etv2 expression in TAECs of wild-type control 
(n = 5), Tie2-Cre;Etv2 CKO (n = 7), and VEC-Cre;Etv2 CKO (n = 7) mice on day 13 after tumor cell transplantation (ptt). (B) Tumor growth in control, 
VEC-Cre;Etv2, and Tie2-Cre;Etv2-CKO mice. Tumor volume was measured on days 6, 9, 12, 15, 18, and 21 ptt (n = 7/group) (*P < 0.05, **P < 0.01, ***P 
< 0.001). (C) Representative images for CD31 (red) immunofluorescence and quantification of CD31+ vessel density of the tumor sections (n = at least 
10/group). LLC-GFP cells (blue) and nuclei counterstained with DAPI (gray) are shown. Scale bars: 100 μm. Tumors were harvested from littermate 
control (wild-type), Tie2-Cre;Etv2 CKO, and VEC-Cre;Etv2-CKO mice on day 21 ptt. (D) qRT-PCR analysis of Fli1, Erg, and Ets1 expression in TAECs of 
littermate control (WT) and Tie2-Cre;Etv2-CKO mice on day 15 ptt (n = 4/group). Data are presented as mean with standard deviation for all measure-
ments. Statistical significance was analyzed by either a 2-tailed Student’s t test (D), 1-way ANOVA with Dunnett’s multiple-comparison test (A and 
C), or 2-way repeated-measures ANOVA with Tukey’s multiple-comparison test (B).
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2PM analysis reveals that Etv2-deficient tumor vessels are similar to steady-state vessels. We examined the 
effect of  Etv2 loss on the morphology and function of  the tumor-associated vasculature in vivo using 
2-photon microscopy (2PM). 2PM induces less photodamage than confocal microscopy and has high-
er spatiotemporal resolution (~30 fps and <0.5 μm/pixel) than magnetic resonance imaging, computed 
tomography, and positron emission tomography (34). To assess Etv2-deficient tumor vessels, we trans-
planted LLC-GFP cells into the ear pinna of  Etv2-CKO mice, performed in vivo 2PM, and assessed vessel 
morphology. In wild-type mice, tumor-associated vessels, compared with steady-state vessels, had distinct 
tortuous morphology, larger diameter, and functional abnormalities, including sluggish blood flow and 
increased leakiness, as previously observed (35). However, tumor-associated vessels in Etv2-CKO mice 
resembled those of  steady-state vessels (Figure 3, A–E, and Supplemental Video 1). It is important to note 
that the vessels of  the control and Etv2-CKO mice were similar in steady states (Supplemental Figure 3A). 
Next, to better assess tumor-associated changes to the vascular network, we created 3D contour surfaces 
Figure 3. In vivo assessment of tumor-associated vessel morphology in Etv2-CKO mice. 2PM was performed on anesthetized mice to assess vessel mor-
phology in (A and B) wild-type (WT+LLC) and (C and D) Tie2-Cre;Etv2-CKO (Tie2Cre, Tie2Cre+LLC) tumor-bearing mice. Images show that LLC tumor (green) 
is associated with vascular remodeling and the growth of larger tortuous and irregular capillaries (red) and collagen fibers (second harmonic generation 
signal, blue). Scale bar: 10 μm. (E) Average capillary diameter in steady-state vessels (WT, black dots) and tumor-associated capillaries in littermate con-
trol (WT+LLC, blue dots) and CKO (Tie2-Cre+LLC, red dots) mice (n = 5/group; at least 10 capillaries were measured per mouse; *P < 0.05, **P < 0.01). (F) 
Vessel complexity was analyzed by generating 3D contour surfaces to identify vessels (Supplemental Video 1) and counting the number of discrete vessel 
segments in each image (n = at least 8/group; ***P < 0.001). (G) Vessel volume is plotted for each group, with the middle line in each bar representing the 
average volume of vessel segments in an image (n = 5/group; *P < 0.05, ***P < 0.001). (H) A plot of average pixel intensity counts for each group fitted to 
an exponential probability distribution function using maximum likelihood estimation methods to extract the rate of decay for each group (n = 4/group;  
*P < 0.05). Data are presented as mean with standard deviation for all measurements. Statistical significance was analyzed by 1-way ANOVA with Dun-
nett’s multiple-comparison test (E–G) or 2-way repeated-measures ANOVA with Tukey’s multiple-comparison test (H).
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Figure 4. Etv2 regulates tumor endothelial cell–specific Flk1. (A) qRT-PCR analysis of Flk1 expression in lung ECs (LECs) and tumor ECs (TAECs) obtained 
from littermate control (WT) and Tie2-Cre;Etv2-CKO mice on day 15 ptt (n = 5/group). (B) qRT-PCR analysis of Etv2 expression in CD31+CD45– ECs obtained 
from tumors of Gfp shRNA– (control) and Etv2 shRNA–treated mice on day 15 ptt. Data are shown as percentage relative expression of control shRNA 
group (n = 4/group). Tumor growth in Gfp shRNA– (control) and Etv2 shRNA–treated mice (n = 6 control, 7 Etv2 shRNA; *P < 0.05, **P < 0.01,***P < 0.001). 
(C–E) Representative images and quantification for (C) CD31 (red) (n = 25/group), (D) Ki67 (green), and (E) pFLK1 (Y951) (green) (n = 12/group) immunoflu-
orescence of tumor sections. LLC-GFP cells (blue) and nuclei counterstained with DAPI (gray) are shown. White arrows indicate the expression of Ki67 (D) 
and pFLK1 (E) in tumor vessels. Scale bars: 100 μm (C); 50 μm (D and E). (F–H) Fgfr1, Fgfr2, and Fgfr3 expression in TAECs of littermate control (WT) and 
Tie2-Cre;Etv2-CKO mice on day 15 ptt (n = 5/group). (I) Lung ECs (LEC) of littermate control (WT) or Tie2-Cre;Etv2-CKO mice were sorted and subjected to 
a cell proliferation assay. Data are shown as a percentage of control (0.5% serum) (n = 4/group). (J) Aortas from the controls (WT) and Tie2-Cre;Etv2-CKO 
mice were subjected to an angiogenic sprouting assay, and the mean sprout number and length were measured 8 days later (n = 5 or more/group). Data are 
presented as mean with standard deviation for all measurements. Statistical significance was analyzed by either a 2-tailed Student’s t test (B, left, C, and 
E–H), or 2-way ANOVA with Sidak’s (A, I, and J) or 2-way repeated-measures ANOVA with Tukey’s (B, right) multiple-comparison test.
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of  all vessels in the images, including capillaries and larger venules and arterioles, to quantify the number 
of  discontinuous vessel segments, as a measure of  network complexity and the volume of  each vessel seg-
ment. Tumors growing in wild-type mice showed increased vessel complexity and decreased average ves-
sel segment volume, compared with steady-state vessels, suggesting the expansion of  tumor capillaries via 
angiogenesis (Figure 3, F and G, and Supplemental Figure 3, B and C). However, tumors growing in Etv2-
CKO mice had similar vessel complexity and average vessel segment volume compared with steady-state 
vessels (Figure 3, F and G, and Supplemental Figure 3, B and C), suggesting that new capillary formation 
requires Etv2. Finally, we evaluated vessel integrity in the tumor-bearing mice by plotting the average pixel 
intensity counts and identified extravascular leakage by an increase in intermediate pixel intensity counts 
in the red channel (10–80 gray levels, zoomed inset) and, when fitted to an exponential curve, a lower rate 
of  decay. Tumor-associated vessels were significantly leakier than steady-state vessels in wild-type mice, 
whereas, the leakage was significantly reduced in Etv2-CKO mice (Figure 3H and Supplemental Figure 
3D). We additionally performed a kymograph analysis on representative images to further validate vessel 
integrity of  the Etv2-deficient tumor vessels. While tumor-associated vessels in wild-type mice showed 
noticeable broadening of  the intensity profile and higher extravascular dextran signal, tumor-associated 
vessels in the Etv2-CKO mice had sharp well-delineated vessel edges and little extravascular dextran signal 
(Supplemental Figure 3E and Supplemental Video 2). These data suggested that Etv2-deficient tumor ves-
sels, in the absence of  new angiogenesis, remained similar to steady states.
ETV2 regulates VEGF response in TAECs. VEGF is crucial for tumor angiogenesis. Previous studies have 
established positive feedback regulation between Etv2 and Flk1 expression in development (19, 36). We 
therefore determined if  Etv2 deficiency might lead to defects in VEGF responsiveness in TAECs. Flk1 
expression was similar in steady-state ECs from both wild-type and Etv2-CKO mice. However, while Flk1 
expression was readily upregulated in TAECs in the wild-type mice, Flk1 expression in the Etv2-deficient 
TAECs remained similar to that of  steady-state ECs (Figure 4A). As expected, intratumoral lentiviral 
Etv2 shRNA injection significantly inhibited Etv2 expression in the TAECs, reduced TAEC proliferation, 
and restricted tumor growth and angiogenesis (Figure 4, B–D, and Supplemental Figure 4A). Important-
ly, tumor-associated vessels, but not the nontumor vessels, had reduced activating phosphorylation of  
FLK1 (37) after Etv2 shRNA injection, suggesting that Etv2 regulates Flk1 expression and activation in a 
TAEC-specific manner (Figure 4E and Supplemental Figure 4C). Notably, Etv2 deficiency does not appear 
to disturb FGF signaling, as expression of  Fgfr1, Fgfr2, and Fgfr3 in both TAECs and nontumor ECs was 
similar in wild-type and Etv2-CKO mice (Figure 4, F–H, and Supplemental Figure 4C). Notably, Etv2-defi-
cient lung ECs showed reduced proliferation to VEGF stimulation, but not FGF2, compared with controls 
(Figure 4I). Additionally, Etv2-deficient aortas displayed diminished VEGF-induced, but not FGF2-in-
duced, sprouting in aortic ring assay (38) (Figure 4J and Supplemental Figure 4D). Moreover, lenti-Etv2 
shRNA–infected yolk sac–derived endothelial (YSE) cells displayed defective tube formation in response to 
VEGF, but not FGF2, compared with wild-type YSE cells (Supplemental Figure 4E). Taken together, these 
results indicate that Etv2 regulates VEGF singling in TAECs.
ROS activate Etv2 expression. Developmental angiogenesis is controlled by changes in O2 tension (39, 40). 
Moreover, oxidative stress underlies many of the characteristics of cancer (41). Particularly, ROS, increased in 
response to ischemia, hypoxia, inflammation, or growth factors, such as VEGF and angiopoietin-1, play a criti-
cal role in angiogenesis (42). Thus, we determined if  ROS could trigger Etv2 expression in TAECs. Higher ROS 
levels were detected in TAECs compared with steady-state lung or hind limb ECs (Figure 5A). Remarkably, 
Etv2, Flk1, or Vegf expression was greatly upregulated by H202 or L-buthionine-S,R-sulfoximine (BSO) in YSE 
cells (Figure 5, B–D, and Supplemental Figure 5, A–C). ROS also increased the expression of other Ets factors, 
including Ets1, Ets2, and Elk3 in YSE cells (Figure 5E). Additionally, 24-hour hypoxia followed by 24-hour 
reoxygenation, which mimics the pathophysiological ischemia/reperfusion condition (43, 44), or even 24-hour 
hypoxic exposure alone increased ROS and upregulated Etv2 expression in YSE cells; ROS scavengers inhibit-
ed this Etv2 expression (Figure 5F and Supplemental Figure 5, D and E). Remarkably, systemic ROS scavenger 
treatment reduced Etv2 expression in the TAECs and reduced tumor growth in vivo (Figure 5G).
Etv2 siRNA nanoparticles effectively inhibit tumor angiogenesis and tumor growth. As Etv2 expression is 
silent in steady-state ECs, we speculated that a systemic anti-Etv2 strategy could effectively block Etv2 
expression in TAECs, without causing any potential vascular adverse effects. To test this idea, we first 
determined if  the Etv2 shRNA used was specific for inhibiting Etv2 but not other Ets factors. Particularly, 
YSE cells infected with Etv2 shRNA, upon H2O2 treatment, greatly suppressed Etv2 upregulation, whereas, 
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upregulation of  other Ets genes, including Fli1, Ets1, Ets2, and Elk3, was not affected, establishing the 
selectivity of  Etv2 shRNA in inhibiting Etv2 (Supplemental Figure 6A). Next, we formulated nanopar-
ticles composed of  Etv2 siRNA (using the same sequence as the shRNA) and a self-assembling peptide 
carrier (“p5RHH”), which has been previously described (45) and used to deliver p65NF-kB siRNA to 
inhibit experimental arthritis (46, 47). The p5RHH-siRNA nanoparticles (~55-nm diameter) protect the 
siRNA from serum deactivation, while avoiding reticuloendothelial system uptake and deliver functional 
oligonucleotides to inflammatory targets (45, 47, 48). We injected Etv2 siRNA peptide nanoparticles 
through tail vein into the tumor-bearing mice, from days 9–17 ptt, 5 times, every other day. The nanopar-
ticles reached the tumor effectively within 24 hours of  the injection (Figure 6, A and B). Etv2 expression 
in TAECs and tumor growth and tumor angiogenesis were dramatically reduced, starting from 2 days 
Figure 5. ROS trigger Etv2 expression. (A) ROS levels in ECs obtained from lung (LEC), hind limb tissue (HLEC), or tumor (TAEC) (n = 3 or more/group). (B–
E) qRT-PCR analysis of expression of (B) Etv2, (C) Flk1, (D) Vegf, and (E) Ets factors Elk3, Ets1, and Ets2 in H2O2-treated yolk sac–derived endothelial (YSE) 
cells (n = 4 or more/group). (F) Etv2 expression in YSE cells underwent with 24-hour hypoxia (<1% oxygen), followed by 24-hour normoxia (H/R) with/
without ROS scavengers N-Acetyl cysteine (NAC; 5 mM) and apocynin (APO; 100 mM) (n = 4 or more/group). (G) Etv2 expression in TAECs isolated from 
untreated and NAC+APO-treated mice on day 14 ptt. Tumor growth in untreated and NAC+APO-treated mice. Mice were treated with daily i.p. injections 
of vehicle or a combination of NAC (200 mg/kg) and APO (50 mg/kg) for 10 days, from day 4 to day 13 ptt (n = 5 vehicle, 7 NAC+APO) (**P < 0.01, ***P < 
0.001). Data are presented as mean with standard deviation for all measurements. Statistical significance was analyzed by either a 2-tailed Student’s t 
test (G, left), 1-way ANOVA with Dunnett’s (B–F) or Bonferroni’s multiple-comparison test (A), or 2-way repeated-measures ANOVA with Sidak’s multiple 
comparison test (G, right).
9insight.jci.org   https://doi.org/10.1172/jci.insight.97349
R E S E A R C H  A R T I C L E
after the first nanoparticle injection (Figure 6, C–E). An extended treatment scheme (days 5–23 ptt, 10 
times, every other day) continuously attenuated the tumor progression until the end of  the study on day 
29 ptt (Supplemental Figure 6B). Importantly, proliferation and FLK1 activation were inhibited in the 
TAECs of  Etv2 siRNA peptide nanoparticle–treated mice (Figure 6, F–H).
Figure 6. Systemic treatment with Etv2 siRNA peptide nanoparticle restricts tumor growth and tumor angiogenesis. (A) IVIS imaging of whole-body 
and isolated tumor at 24 hours after the injection of Quasar705-tagged Etv2 siRNA peptide nanoparticles through the tail vein. (B) Representative images 
from a fluorescence microscope for Quasar705-tagged Etv2 siRNA nanoparticles (purple) in the tumor sections at 24 hours after the injection. (C) qRT-PCR 
analysis of Etv2 expression in TAECs isolated from scrambled and Etv2 siRNA nanoparticle–treated mice on day 15 ptt (n = 5/group). (D) Tumor growth in 
the scrambled and Etv2 siRNA nanoparticle–treated mice. Scrambled and Etv2 siRNA nanoparticles were injected through the tail veins of the mice on 
days 9, 11, 13, 15, and 17 ptt (n = 8 scrambled, 10 Etv2 siRNA; **P < 0.01, ***P < 0.001). Representative images of mice with tumor from the treatment and 
control groups. (E–H) Representative images and quantification for (E) CD31 (red), (F and G) Ki67 (green), and (H) pFLK1 (Y951) (green) immunofluorescence 
of the tumor sections (n = 7 or more/group). LLC-GFP cells (blue) and nuclei counterstained with DAPI (gray) are shown. White arrows indicate the expres-
sion of (F) Ki67 and (H) pFLK1 in tumor vessels. Scale bars: 200 μm (B); 100 μm (E); 50 μm (F and H). Data are presented as mean with standard deviation 
for all measurements. Statistical significance was analyzed by either a 2-tailed Student’s t test (C, E, G, and H) or 2-way repeated-measures ANOVA with 
Sidak’s multiple-comparison test (D).
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Figure 7. Etv2 siRNA peptide nanoparticle treatment do not adversely affect cardiovascular system and function. Wild-type mice were intrave-
nously treated with vehicle, scrambled siRNA, or Etv2 siRNA nanoparticles for 5 times, every other day. (A) Systolic, diastolic, and mean blood pres-
sure measurements in control (vehicle and scrambled siRNA nanoparticles) or Etv2 siRNA nanoparticle–treated mice (n = 5/group). (B and C) Pressure 
diameter measurements of the (B) ascending aorta and (C) carotid artery over a range of pressures from 0 to 175 mmHg (n = 5/group). (D) Heart rate, 
left ventricular mass, left ventricular mas index, relative wall thickness, left ventricular posterior wall end diastole, left ventricular posterior wall end 
systole, left ventricular internal diameter end diastole, left ventricular internal diameter end systole, intraventricular septal end diastole, intraven-
tricular septal end systole, and percentage fractional shortening in control (vehicle and scrambled siRNA nanoparticles) or Etv2 siRNA nanoparticle–
treated mice, measured by echocardiogram analysis (n = 5/group). (E) Representative images of H&E-stained sections of heart, lungs, kidney, and 
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Etv2 siRNA nanoparticles do not elicit cardiovascular side effects. Antiangiogenic therapies, such as anti-
VEGF treatments, often have systemic and vascular side effects that complicate and, at times, diminish 
the outcome of  the treatment (4), as commonly targeted VEGF is also required for vascular homeostasis 
(6, 7). Prior work has shown that the p5RHH-based nanoparticles exert no untoward immune stimulation, 
complement activation, and appreciable toxicity toward blood components or major organs after multiple 
systemic doses (46). To assess the safety profile of  our employed Etv2 siRNA peptide nanoparticle treat-
ment in cardiovascular systems, we injected the Etv2 siRNA nanoparticles into wild-type mice (5 times, 
every other day). Following the treatment, systolic, diastolic, and mean blood pressures (49) were similar in 
the treated and control groups (Figure 7A). Pressure-diameter measurements, commonly used to evaluate 
vessel mechanics (50), showed that the compliances of  the ascending aorta and carotid artery were equiva-
lent for the treated and control groups (Figure 7, B and C). Clinically relevant cardiac functions, including 
left ventricular interior and posterior wall diameters following systole and diastole, relative wall thickness, 
mass index, and fractional shortening, were normal and equivalent across treated and control groups in 
echocardiogram analysis (Figure 7D). Additionally, histological inspection of  the H&E-stained samples of  
major vascular organs revealed no pathological abnormalities (Figure 7E). To better understand the phar-
macokinetics of  the Etv2 siRNA nanoparticles, we injected a separate group of  mice with a single dose of  
the siRNA nanoparticles and performed high-performance liquid chromatography (HPLC) on the blood 
samples. After the i.v. administration of  0.5 nmol of  the siRNA nanoparticles to each wild-type mouse, the 
siRNA nanoparticle plasma concentrations were still detectable at 3 hours (Supplemental Figure 7). The 
mean elimination half-life of  siRNA nanoparticles was calculated as 43 ± 27 minutes (Supplemental Figure 
7). Together, these data suggest that Etv2 siRNA nanoparticle-based drugs can be considered in the future 
to inhibit tumor angiogenesis without any obvious cardiovascular side effects.
Discussion
ETS factors have been found to play a role in tumorigenesis (51). However, most studies are restricted 
to tumor cell–intrinsic effects. Thus, despite their prominent roles in developmental angiogenesis (13, 
27, 28), there have been limited studies on ETS factors in tumor angiogenesis (52, 53). Herein, we 
show that while Etv2 expression is silent in adult steady-state ECs, it is reactivated in TAECs in both 
humans and mice. Importantly, Etv2-deficient mice supported reduced tumor growth and angiogenesis. 
Etv2-deficient tumor vessels remained similar to physiological steady-state vessels. Previous studies have 
established that tumor angiogenesis is sensitive to oxygen tension. Particularly, the tumor environment 
is known to be hypoxic, and hypoxia induces angiogenesis through activating HIF1α and VEGF pro-
duction (40, 42). Importantly, developmental angiogenesis is also regulated by oxygen tension (39, 54). 
Our data suggest that Etv2 is a redox-sensitive transcription factor, which is induced by ROS in TAECs. 
We show that ROS levels were elevated in TAECs. ROS scavenging inhibited Etv2 upregulation in 
TAECs. These studies enforce the notion that the genetic programs regulating developmental processes 
are recapitulated in the pathologic disease processes.
Recent studies have established that the interplay among ETV2, VEGF, and its receptor VEGFR2 
(also known as FLK1) is essential for hematopoietic and vascular development (19, 36). We have recently 
demonstrated that the VEGF/FLK1 pathway is also required downstream of  ETV2 in EC regeneration 
(32). As in development and EC regeneration, the VEGF/FLK1 pathway seems to be the target of  ETV2 in 
tumor angiogenesis. In particular, while Flk1 expression levels were elevated in wild-type TAECs, compared 
with steady-state vessels, Flk1 expression levels in Etv2-deficient TAECs were similar to steady-state vessels. 
Moreover, Etv2-deficient ECs showed decreased endothelial proliferation, tube formation, and sprouting 
response to VEGF, not FGF, compared with wild-type ECs. Thus, an important implication of  our study 
is that VEGF targeting in TAECs maybe selectively achieved through Etv2 inhibition. Intriguingly, other 
Ets genes were greatly upregulated in Etv2-deficient TAECs. However, upregulation of  other Ets genes was 
not apparently sufficient to overcome Etv2 deficiency in tumor angiogenesis. Potential compensatory mech-
anisms involving FGF signaling and other Ets factors in the residual tumor growth in Etv2-deficient mice 
need to be investigated in the future.
liver harvested from control (vehicle and scrambled siRNA nanoparticles) or Etv2 siRNA nanoparticle–treated mice (original magnification, ×20). Data 
are presented as mean with standard deviation for all measurements. Statistical significance was analyzed by either 1-way ANOVA with Bonferroni’s 
multiple-comparison test (A and D) or 2-way repeated-measures ANOVA with Tukey’s multiple-comparison test (B and C).
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Currently, many RNAi-based drugs, including Vegf, Epha2, and Vegfr1, are in clinical trials, phase I or 
II (55–57), to inhibit tumor angiogenesis. In the present work, we sought to define the utility of  a siRNA 
delivery approach using nanoparticles targeted to the Etv2. The nanoparticle construct is composed of  
a self-assembling peptide (p5RHH) siRNA complex that serves to protect the siRNA from serum deac-
tivation, while avoiding reticuloendothelial system uptake and delivering functional oligonucleotides to 
inflammatory targets (45–47). Key features of  the complex that promote sequentially coordinated endo-
somal uptake, endosomal lysis, and siRNA release depend on specific molecular features of  the carrier 
peptide, which is derived through modification of  the bee venom peptide melittin (48). Selected amino 
acid truncations and substitutions mitigate the undesirable pore-forming capacity of  peptide, yet retain 
its ability to condense siRNA and facilitate endosomal escape, as previously reported (58). A simple 
mixing procedure of  only 10 minutes yields a complex that is small enough (~55 nm) to passively diffuse 
rapidly into inflamed tissues, where it is retained, yet it avoids hepatic sequestration (48). Using a mouse 
tumor transplantation model, we demonstrated that systemic Etv2 siRNA-p5RHH nanoparticle delivery 
can effectively inhibit tumor angiogenesis, without eliciting any cardiovascular side effects. Future inves-
tigations on p5RHH-siRNA nanoparticles as a safe and effective clinical tool instead of  viral vectors for 
delivering siRNA are warranted. Optimizing anti-Etv2 strategy and delineating Ets factor redundancy 
and potential compensatory pathways in Etv2-deficient TAECs would be critical for improved and selec-
tive clinical antiangiogenic interventions. Potentially, combined chemotherapy and/or immunotherapy 
with Etv2 blockade, leading to vessel normalization, could be beneficial for future treatment of  solid 
tumors. Moreover, the role of  Etv2 in the proangiogenic function of  hematopoietic cells in the tumor 
microenvironment should also be addressed in the future studies. In summary, we have demonstrated 
that Etv2 is, to our knowledge, a novel and critical molecular marker specific for activated ECs and that 
targeting Etv2 is a valid approach for inhibiting tumor angiogenesis.
Methods
Mice. Tie2-Cre;Etv2-CKO, VEC-Cre;Etv2-CKO, and Vav-Cre;Etv2-CKO mice were generated as described 
previously (32, 33). C57BL/6J mice were used as wild-type mice. Tie2-Cre;Etv2f/f mice were used as Tie2-
Cre;Etv2-CKO mice. VECadherin-Cre;Etv2f/f mice were used as VECadherin-Cre;Etv2-CKO mice. Vav-Cre;Et-
v2f/f mice were used as Vav-Cre;Etv2-CKO mice. Littermate subjects were used as controls with the CKO 
mice. Both male and female mice were used in an equal quantity in any given experiment. The ages of  
the experimental animals were between 10 and 12 weeks. Animals were randomly distributed into groups 
when different treatments, such as Etv2 shRNA or Gfp shRNA treatment, N-acetyl cysteine plus apocynin 
(NAC+APO) or vehicle treatment, and Etv2 siRNA or scrambled siRNA nanoparticle treatment, were 
employed. A group of  technicians was in charge of  distributing and codifying the experimental animals. 
The investigators were not aware of  the group allocation until the treatment, data collection, and data 
analysis were done.
Cell lines. LLC-GFP cells were obtained from Alexander S. Krupnick, Washington University in St. 
Louis (St. Louis, Missouri, USA). B16F10 melanoma cells were purchased from ATCC. YSE cells were 
obtained from Laurence A. Lasky (Genentech, South San Francisco, California, USA). All cell lines have 
been tested negative for mycoplasma contamination.
Human tumor samples. Deidentified patient-derived, formalin-fixed and paraffin-embedded (FFPE), 
malignant and matched nonmalignant breast, lung, prostate, and colon tissue specimens were collected 
from Tissue Procurement Core (TPC) Siteman Cancer Center at Washington University School of  Med-
icine. TPC performs pathological reviews to determine the malignant versus nonmalignant status of  the 
tissues following standard procedures before disseminating the tissue for downstream applications. Accord-
ing to TPC definition, any section associated with equal to or more than 1 neoplastic cell was considered 
malignant. However, most of  our samples had more than 50% neoplastic cells in any given section. A sum-
mary of  the pathological review of  the tissues that we received and the SOP for TPC Pathology Specimen 
Review is provided in the supplemental materials (Supplemental Table 2 and Supplemental File 1)
Tumor transplantation studies. LLC-GFP cells were cultured in growth medium consisting of  DMEM 
(Gibco) supplemented with 10% (v/v) FBS, 100 unit/ml penicillin, and 100 μg/ml streptomycin. For tumor 
transplantation studies, 1 ml of  growth factor–reduced Matrigel (catalog 354248; Corning) was mixed with 
1 ml tumor cell suspension (2 × 106/ml in PBS); 100 μl tumor cell–Matrigel mixture was injected into the 
back of  mice subcutaneously. Tumor growth was measured by a digital slide calipers (VWR International) 
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at indicated days after tumor cell injection. Tumor volume was calculated by the equation, volume = (larg-
est diameter) × (smallest diameter)2 × 0.5.
Immunofluorescence. FFPE human tissue sections were processed for antigen retrieval using DIVA 
Decloaker (catalog DV2004, Biocare Medical), blocked using freshly made blocking buffer (3% essentially 
IgG free BSA, catalog A9085, MilliporeSigma; 0.3% Triton X-100; and Fc blocker, catalog 422301, Bio-
legend) to prevent nonspecific binding, incubated overnight at 4°C with mouse anti-human CD31 (1:100) 
(catalog MA5-13188, ThermoFisher Scientific) and rabbit anti-human ETV2 (1:300) (catalog ab181847, 
Abcam) primary antibodies, and finally visualized with Alexa Flour 594–labeled goat anti-mouse (1:400) 
(catalog R37121, ThermoFisher Scientific) and Alexa Fluor 647–labeled goat anti-rabbit (1:500) (catalog 
A-21245, ThermoFisher Scientific) secondary antibodies for 2 hours at room temperature. Later, the sec-
tions were processed to counterstain nuclei with DAPI (catalog D1306, ThermoFisher Scientific), cured 
with ProLong Diamond Antifade mountant (catalog P36970, ThermoFisher Scientific) for 24 hours, and 
finally sealed with nail polish for preservation. No primary antibody control, isotype control (Mouse IgG1 
Isotype Control, catalog ab91353, Abcam, and Rabbit IgG Isotype Control, catalog ab172730, Abcam), 
and absorption control (using ETV2 Antibody Blocking Peptide at a 5:1 ratio with employed ETV2 anti-
body, catalog LS-E910, LifeSpan Biosciences) were used as negative controls for immunofluorescence 
staining. The stained sections were examined using the Olympus Fluoview 1200 confocal microscope and 
minimally processed with Imaris (Bitplane) software to prepare the figures. At least 6 pictures from every 
section were processed using ImageJ software (NIH) to quantify CD31+ and ETV2+ areas.
In mouse tumor transplantation studies, before harvesting the tumors, the mice underwent transcardi-
ac whole-body perfusion of  10% buffered formalin. Harvested tumors were thin sliced and fixed in 10% 
buffered formalin for 36 hours, immersed in 30% (w/v) sucrose solution for 48 hours to cryoprotect the 
tissue, frozen in NEG-50 frozen section medium (catalog 6502, ThermoFisher Scientific) using liquid 
nitrogen and 2-methylbutane, and sectioned (16-μm thick) using a Cryostat Cryocut Microtome (Leica, 
CM1850). Tissue sections were first blocked using freshly made blocking buffer (3% essentially IgG free 
BSA, catalog A9085, MilliporeSigma; 0.3% Triton X-100; and Fc blocker, catalog 101301, Biolegend) to 
prevent nonspecific binding; then incubated overnight at 4°C with hamster anti-mouse CD31 (1:400) (cat-
alog MA3105, ThermoFisher Scientific), along with rabbit anti-mouse ETV2 (1:200) (catalog orb156791, 
Biorbyt) or rabbit anti-mouse pFLK1 (Y951) (1:200) (catalog 4991S, Cell Signaling Technology) or rabbit 
anti-mouse Ki67 (1:200) (catalog Ab15580, Abcam) primary antibodies; and finally visualized with Alexa 
Fluor 568–labeled goat anti-hamster (1:500) (catalog A-21112, ThermoFisher Scientific) and Alexa Fluor 
647–labeled goat anti-rabbit (1:500) (catalog A-21245, ThermoFisher Scientific) secondary antibodies for 
2 hours at room temperature. Later, the sections were processed to counterstain nuclei with DAPI (cata-
log D1306, ThermoFisher Scientific), cured with ProLong Diamond Antifade mountant (catalog P36970, 
ThermoFisher Scientific) for 24 hours, and finally sealed with nail polish for preservation. No primary anti-
body control, isotype control (Armenian Hamster IgG Isotype Control, catalog 14-4888-85, ThermoFish-
er Scientific, and Rabbit IgG Isotype Control, catalog ab172730, Abcam), and absorption control (using 
ETV2 Antibody Blocking Peptide in a 5:1 ratio with employed ETV2 antibody, catalog LS-E910, LifeSpan 
Biosciences) were used as negative controls for immunofluorescence staining. The stained sections were 
examined using the Olympus Fluoview 1200 confocal microscope system and minimally processed with 
Imaris (Bitplane) software to prepare the figures. At least 5 pictures from every section were processed using 
ImageJ software (NIH) to quantify CD31+, ETV2+, pFLK1+, and Ki67+ areas.
To further confirm the specificity of  the ETV2 antibody staining, we employed the iEtv2 embryon-
ic stem (ES) cell system that expresses ETV2-V5 in a doxycycline-inducible manner, following protocol 
described previously (17, 19). Briefly, doxycycline-treated iEtv2 ES cells (cultured on Matrigel-coated 
coverslips) were fixed with ice-cold methanol for 10 minutes at room temperature. After fixation, the ES 
cells were first blocked using freshly made blocking buffer (10% Normal Goat Serum, catalog 5425S, Cell 
Signaling Technology, in 1× TBS) to prevent nonspecific binding, then incubated overnight at 4°C with 
rat anti-V5 antibody (1:1,000) (catalog ab206571, Abcam) and rabbit anti-mouse ETV2 (1:1,000) (catalog 
orb156791, Biorbyt), and finally visualized with Alexa Fluor 488–labeled goat anti-rabbit (1:500) (catalog 
ab150077, Abcam) and Alexa Fluor 568–labeled goat anti-rat (1:500) (catalog ab11077, Abcam) second-
ary antibodies for 1 hour at room temperature. Later, the cells were processed to counterstain nuclei with 
DAPI (catalog D1306, ThermoFisher Scientific), cured with ProLong Diamond Antifade mountant (cata-
log P36970, ThermoFisher Scientific) for 12 hours, and finally sealed with nail polish for preservation. The 
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stained cells were examined using the Olympus Fluoview 1200 confocal microscope system and minimally 
processed with Imaris (Bitplane) software to prepare the figures. The data show that both the ETV2 and V5 
tag were present in nuclei and perinuclear spaces, confirming the specificity of  the Etv2 staining (Supple-
mental Figure 1, C and D).
Lung EC isolation. Lungs were harvested from the mice, dissociated into single-cell suspension by using 
a digestion buffer consisting of  Collagenase II (catalog 17101-015, ThermoFisher Scientific) and Deoxyri-
bonuclease 1 (catalog LS002139, Worthington) solution for 30 minutes, stained with rat anti-mouse CD31 
(catalog 102501, Biolegend) conjugated magnetic sheep anti-rat IgG Dynabeads (catalog 11035, Ther-
moFisher Scientific), and CD31+ cells were sorted using MACS. Afterward, sorted CD31+ ECs were either 
cultured with M199 medium containing 20% (v/v) FBS and EC growth supplement (catalog E2759, Milli-
poreSigma) or directly processed for total RNA isolation by the RNeasy mini kit (catalog 74104, Qiagen), 
following the manufacturer’s instructions.
TAEC isolation. Tumors were harvested from the mice, dissociated into single-cell suspension using a 
digestion buffer consisting of  Collagenase i.v. (catalog LS004188, Worthington), Dispase (catalog 17105-
041, ThermoFisher Scientific), and Deoxyribonuclease 1 (catalog LS002139, Worthington) for 90 minutes 
at 37oC and stained with PE-Cy7 anti-mouse CD31 (catalog102418, Biolegend) and APC anti-mouse CD45 
(catalog103112, Biolegend) antibodies. GFP–CD45–CD31+ ECs were FACS sorted using BD FACSAria II 
(BD Bioscience). Sorted ECs were processed for total RNA isolation by the RNeasy mini kit (catalog 
74104, Qiagen) following the manufacturer’s instructions. At least 5 independent tumors per group were 
used for gene expression analysis.
qRT-PCR. RNA and cDNA were prepared according to the manufacturers’ protocols (Qiagen and 
Quantabio, respectively). Gene expression was measured by quantitative RT-PCR using primers detailed in 
the Supplemental Table 1.
Two-photon imaging and analysis of  vessel morphology. For 2-photon (2P) imaging experiments, tumor cells 
were implanted in the ear pinna (and in some cases the hind flank) by injecting 10 μl LLC-GFP and Matri-
gel mixture (2 × 106 cells/ml). Twenty-one days after tumor implantation, mice were anesthetized with 
isofluorane and placed in a custom chamber for imaging. 2PM was performed noninvasively through skin. 
Blood vessels were labeled with a retro-orbital injection of  either 70-kDa Rhodamine Dextran (50 μl, ~1 μg; 
catalog D1824, ThermoFisher Scientific) or 655 nm Q-dots (15 μl; catalog Q21321MP, Invitrogen). Multiple 
images were collected near the tumor margin using a custom-built 2PM system equipped with a Chameleon 
Vision II Ti:Sapp laser and a 20× 1.0 NA Olympus water dipping objective. Each 3D image consisted of  31 
Z-slices taken in 2.5-μm steps. Z-stacks were rendered in 3D, and morphometric analysis was performed to 
assess vessel diameter, the number of  discontinuous segments in the tumor-associated vessel network, and 
the volume of  each vessel segment. Imaris (Bitplane) was used to generate 3D contour surfaces to identify 
vessels (Supplemental Video 1). Surface quality was optimized using background subtraction and threshold-
ing and common settings used across all images. Vessel complexity was determined by counting the number 
of  discrete vessel segments in each image. The volume of  each vessel segment in an image was measured 
and compared across groups by using a linear mixed-effects model where the fixed effects are the treatment 
groups themselves and the random effects are due to intraimage correlation. Normality of  the outcome 
variable was achieved after a log10 transform, and all tests were performed on the transformed data. After the 
model was fitted, pairwise statistical contrasts were used to assess pairwise group differences. Vessel leak was 
variable and was often observed in discreet regions of  an image. Therefore, to minimize selection bias in our 
analysis, we quantified leak by averaging histograms of  maximum intensity projections for all images in each 
group and then plotting average pixel intensity counts for each group. These plots were analyzed by fitting 
them to an exponential probability distribution function using maximum likelihood estimation methods to 
extract the rate of  decay for each group. When extravascular leak was present, it resulted in an increase in the 
intermediate pixel intensity counts (10–80 gray levels) and thus a lower rate of  decay for the plot. Maximum 
likelihood estimates were obtained for each curve, and the estimates were compared by generating a null-hy-
pothesis estimate and a likelihood ratio test to assess a goodness of  fit. Vessel integrity was assessed using a 
standard kymograph analysis on representative images.
Lentiviral Etv2 shRNA production. pLKpuro lentiviral Etv2 shRNA clones, TRCN0000084284 
(NM_007959.1-93s1c1), TRCN0000084285 (NM_007959.1-52s1c1), TRCN0000084286 (NM_007959.1-
887s1c1), and TRCN0000084287 (NM_007959.1-888s1c1), constructed and distributed by the RNAi Con-
sortium at the Broad Institute (https://portals.broadinstitute.org/gpp/public/), were obtained from the 
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McDonnell Genome Institute at Washington University School of  Medicine and funded in part by the 
Children’s Discovery Institute of  Washington University in St. Louis. 293T cells were transfected with 
pLKpuro Etv2 shRNA constructs, pCAG-HIVgp, and pCMV-VSV-G-RSV-Rev (4:3:1) by using the calcium 
phosphate method. Sixteen hours after transfection, media were changed and cells were then grown for 
additional 48 hours. Subsequently, the supernatant was harvested and concentrated by Lenti-X-Concen-
trator (Clontech). The virus titer was determined using the Lenti-X p24 Rapid Titer Kit (Clontech). For 
the intratumor injection, IFU was around 3 × 107/ml. In a preliminary screening with this panel of  Etv2 
shRNA lentiviruses, we identified lentiviral shRNA clone TRCN0000084284 (NM_007959.1-93s1c1) to be 
most effective in restricting tumor growth, and hence, it was used for all subsequent experiments (data not 
shown). Lentiviral Gfp shRNA was used as control treatment.
EC proliferation assay. Lung ECs, previously sorted from wild-type and Tie2-Cre;Etv2-CKO mice, were 
cultured in growth medium consisting of  M199 medium (Gibco), 10% (v/v) FBS, 100 unit/ml penicillin, 
and 100 μg/ml streptomycin. For proliferation assay, cells were plated in 96-well plates (3,000 cells/well). 
One day later, medium was changed to 0.5% serum-containing medium. After 24 hours, VEGF (50 ng/ml) 
or FGF2 (50 ng/ml) was added to the culture. After 3 days, 10 μl CCK-8 (catalog 96992, MilliporeSigma) 
solution was added to each well, and the plates were incubated for 3 hours at 37°C. Absorbance at 450 nm 
(A450) for each well was measured.
Aortic ring assay. The aortic ring assay was performed as previously described (1, 38). Briefly, aortas 
were retrieved from control or Tie2-Cre;Etv2-CKO mice, cut into rings approximately 0.5 mm in width, and 
cultured for 24 hours in serum-free culture medium. Subsequently, aortic rings were embedded into Matri-
gel (catalog 356231, Corning), and culture medium containing 2.5% FBS and VEGF (50 ng/ml) or FGF2 
(50 ng/ml) was added. Medium was changed on days 3, 5, and 7. Aortic rings were fixed with 4% PFA on 
day 8, and sprout number and sprout length were measured using ImageJ image analysis software (NIH).
Tube formation assay. Wild-type and lentiviral Etv2 shRNA–infected YSE cells, cultured in growth medi-
um consisting of  M199 medium (Gibco), 10% (v/v) FBS, 100 unit/ml penicillin, and 100 μg/ml streptomy-
cin, were kept in 24-hour hypoxia (<1% oxygen), followed by 24-hour normoxia (in which overnight serum 
starvation [0.5% serum] was used). Afterward, cells were plated on a Matrigel-coated (catalog 96992, Corn-
ing) 24-well plate with either VEGF (50 ng/ml) or FGF2 (50 ng/ml) and incubated at 37°C for 5 hours, 
before images were taken with a Leica DFC 310 FX microscope system.
ROS induction, measurement, and scavenger treatment. For ROS induction, wild-type or Etv2 shRNA–infect-
ed YSE cells were plated in 6-well culture plate (1.5 × 105 cells/well). The following day, cells were treated 
with H2O2, BSO, or hypoxic condition (<1%O2) for 24 hours or hypoxia/reoxygenation (24 hours <1% O2, 
followed by 24 hours normoxia). For ROS measurement, YSE or tissue-derived ECs were incubated with PBS 
containing 2.5 μM DCFDA (catalog D399, ThermoFisher Scientific) for 10 minutes at 37°C. Tissue-derived 
cells were stained with PE-Cy7 anti-mouse CD31 (catalog102418, Biolegend) and APC anti-mouse CD45 
(catalog 103112, Biolegend) antibodies. ROS levels in YSE cells or in CD45–CD31+ cells from the tissues were 
measured by BD LSRFortessa (BD Bioscience). For in vitro ROS scavenger treatment, NAC (dissolved in 
water; 5 mM) (catalog A9165, MilliporeSigma) and APO (dissolved in DMSO and later diluted with water; 
100 mM) (catalog 178385EMD, MilliporeSigma) were added to the YSE cells at the beginning of  reoxygen-
ation period for next 24 hours. For the in vivo treatment, NAC (200 mg/kg, dissolved in water) and APO (50 
mg/kg, dissolved in DMSO and later diluted with water) were intraperitoneally injected into the mice.
Preparation of  Etv2 siRNA peptide nanoparticle. For the siRNA nanoparticle treatment study, we 
designed the Etv2 siRNA against the sequence “GAGCGGAATTTGGTTTCTATT” [the sequence of  
the lentiviral shRNA clone TRCN0000084284(NM_007959.1-93s1c1) that was used for the shRNA stud-
ies] and obtained it from MilliporeSigma. MISSION siRNA Universal Negative Control #1 (catalog 
SIC001, MilliporeSigma) was used as scrambled siRNA control. For tracking the distribution of  the 
siRNA, Quasar 705 tagged Etv2 siRNA was obtained from MilliporeSigma. 100 μM siRNA solution 
was prepared by dissolving in 1× siRNA buffer (catalog B-002000-UB-100, Dharmacon) and incubating 
on an orbital mixer (~500 rpm) at 37°C for 70–90 minutes; this stock siRNA was stored in 10 μl aliquot 
at –80°C until use. To prepare the nanoparticle complex, 10 μl of  the siRNA suspension was mixed 
with 5 μl of  20 mM p5RHH peptide solution and 185 μl of  1× HBSS (Gibco) and incubated on ice for 
approximately 7 minutes for the siRNA and peptide to conjugate at a siRNA-to-peptide ratio of  1:100. 
The resultant 200 μl siRNA peptide nanoparticle was immediately injected into the mouse through the 
tail vein to deliver a siRNA dose of  1 nmol/mouse (2, 46).
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IVIS imaging. To track the siRNA distribution after nanoparticles injection, in vivo fluorescence images 
were acquired and analyzed with a Xenogen IVIS Spectrum imaging system (Caliper Life-Sciences). Mice 
were kept under isoflurane inhalation anesthesia during the whole-body image acquisition process. Tumor 
and other major organs were harvested immediately after that and processed for imaging as well. A fixed 
protocol (excitation, 640 nm; emission, 700 nm; exposure time, 2 s; binning factor, 8; f  value, 2; field of  
view, 12.9) was used for image acquisitions at 24 hours after tail vein injection of  nanoparticles containing 
Quasar705-labeled Etv2 siRNA into tumor-bearing wild-type mice. For the noninjected subjects, HBSS was 
injected through tail veins, and images were taken following the same protocol (2, 46).
Blood pressure measurement and compliance studies. Arterial blood pressure and arterial compliance mea-
surements were performed after 5 consecutive injections (every other day) of  vehicle or Etv2 siRNA or 
scrambled siRNA nanoparticles into healthy wild-type mice as described previously (3, 49). Briefly, for 
blood pressure, mice were anesthetized with 1.5% isoflurane and kept on a heating pad to maintain normal 
body temperature and monitored via a rectal thermometer. A 2- to 3-mm midline incision was made in the 
neck; the lobes of  the thymus were separated to expose the right common carotid artery. After clamping 
and making a small nick in the right common carotid artery, a Millar pressure transducer (model SPR-671) 
was introduced and advanced to the ascending aorta. Systolic blood pressure, diastolic blood pressure, and 
heart rate were recorded and analyzed using the PowerLab data acquisition system and LabChart 7 for 
Mac software, respectively (ADInstruments). For compliance studies, following the blood pressure mea-
surement, mice were euthanized under isoflurane anesthesia, and the ascending aorta and the left common 
carotid artery were excised and placed in physiology saline (PSS) at 37°C. After cleaning the fatty tissues, 
vessels were placed on a pressure arteriograph (Danish Myo Technology), maintained in PSS at 37°C, and 
examined with an inverted microscope attached to a CCD camera and a computerized system that allows 
continuous recording of  the vessel diameter measurement (4, 50).
Echocardiography. The Mouse Cardiovascular Phenotyping Core at Washington University School of  
Medicine performed noninvasive cardiac ultrasound examination of  healthy wild-type mice under light 
anesthesia, after 5 consecutive injections of  vehicle or Etv2 siRNA or scrambled siRNA nanoparticle (every 
other day). VisualSonics Vevo-2100 cardiac echocardiography system (FUJIFILM, VisualSonics Inc.) was 
used to characterize the structure and function of  the heart and great vessels.
Histological analysis. Heart, lungs, kidneys, and liver were harvested after 5 injections (every other day) of  
vehicle or Etv2 siRNA or scrambled siRNA nanoparticles into healthy wild-type mice and fixed in 10% buff-
ered formalin for 48 hours. The tissues were decalcified in EDTA solution, embedded in paraffin, and cut to 
5-μm sections. Finally, the sections were stained with H&E. Digital images of 4 random areas per H&E-stained 
organ section were acquired at 20× magnification and checked by a double blinded histologist/pathologist.
Single-dose siRNA nanoparticle administration, blood sampling, HPLC, and pharmacokinetic analysis. Five 
wild-type mice (C57BL/6J; ~17 weeks old) received a single i.v. dose of  siRNA nanoparticle and under-
went PK measurements. A carotid artery catheter was inserted before the siRNA nanoparticle dosing for 
blood sampling. Blood samples were taken prior to and at 10, 40, 90, and 180 minutes after the i.v. admin-
istration of  p5RHH-Cy3 siRNA nanoparticle. Blood drawn was replaced with 80 μl heparinized saline (5 
U/ml) after each collection to avoid volume depletion. Plasma was separated by centrifugation and then 
stored at –80oC until analyzed for siRNA.
Individual plasma samples (~60 μl) were added with 0.4 ml Clarity OTX lysis-loading buffer (Phenome-
nex Inc.). The mixture was vortex mixed for 30 seconds and then loaded onto the solid-phase extraction 
(SPE) cartridge. The siRNA nanoparticles were extracted from individual plasma samples using Clarity 
OTX SPE cartridges with polymeric sorbent (100 mg/3 ml; Phenomenex Inc.). Sorbent was conditioned 
with 1.0 ml methanol and equilibrated with 1 ml of  150 mM NaH2PO4 buffer (pH 5.5) containing 2 mM 
NaN3. For plasma samples, following sample loading, the cartridge was washed with 4.0 ml washing buffer 
(50 mM NaH2PO4 buffer [pH 5.5] containing 50% acetonitrile). The siRNA nanoparticles were eluted with 
1 ml elution buffer (100 mM NH4HCO3 containing 10% tetrahydrofuran and 40% acetonitrile). The eluent 
was evaporated to near dryness using a Savant SC110 SpeedVac concentrator. Samples were reconstituted 
with 100 μl HPLC-grade water, and a 25-μl aliquot was injected into the HPLC column. The HPLC assay 
was carried out using an Agilent series 1200 HPLC system equipped with a binary pump, autosampler, and 
degasser coupled to an Agilent 1260 fluorescence detector. Separation was achieved on an Acquity UPLC 
oligonucleotide BEH C18 column (50 × 2.1 mm, 1.7-μm particle size; Waters Corporation). The analyte 
was eluted using acetonitrile/100 mM hexylammonium acetate (48:52, v/v) as the mobile phase with a 
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flow rate of  0.1 ml/min. The column temperature was set at 60°C. The siRNA nanoparticle was detected 
by use of  an excitation wavelength of  548 nm and an emission wavelength of  566 nm.
A 1-compartment open model with first-order elimination (C = C0 e–kt) was used to characterize drug 
disposition in plasma, where C0 represents siRNA concentration at time 0 and k denotes the first-order 
elimination rate constant. Elimination half-life was calculated as t1/2 = 0.693/k
Statistics. GraphPad Prism 7 software was used for performing statistical analysis and generating 
graphs/plots. Data are presented as mean with standard deviation for all the measurements. All experi-
mental data were reliably reproduced in 2 or more individual biological replicates. Comparison between 
2 independent samples was performed using a 2-tailed Student’s t test. In case of  comparing more than 
2 groups, 1-way ANOVA with post hoc Dunnett’s or Tukey’s or Bonferroni’s multiple-comparison test 
or 2-way ANOVA with either post hoc Tukey’s or Sidak’s multiple-comparison test was used, whichever 
appropriate. Tumor volume data was analyzed using or 2-way repeated measures ANOVA with either post 
hoc Tukey’s or Sidak’s multiple-comparison test. A P < 0.05 was considered statistically significant.
Study approval. Animal husbandry, generation, handling, and experimentation were performed in 
accordance with protocols approved by the Institutional Animal Care and Use Committee of  Washington 
University School of  Medicine in St. Louis.
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